Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Prospective, Randomized, Double‑Blinded, Vehicle‑ and Placebo-Controlled, Multicenter Study to Evaluate the Safety and Preliminary Efficacy of IDCT in Subjects With Single‑Level, Symptomatic Lumbar Intervertebral Disc Degeneration

Trial Profile

A Prospective, Randomized, Double‑Blinded, Vehicle‑ and Placebo-Controlled, Multicenter Study to Evaluate the Safety and Preliminary Efficacy of IDCT in Subjects With Single‑Level, Symptomatic Lumbar Intervertebral Disc Degeneration

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 07 Jan 2019

At a glance

  • Drugs Injectable-discogenic-cell-therapy-DiscGenics (Primary)
  • Indications Intervertebral disc degeneration
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Sponsors DiscGenics
  • Most Recent Events

    • 07 Jan 2019 According to a DiscGenics media release, this trial passed its initial planned safety review, where an independent data safety monitoring committee (DSMC) reviewed the first six subjects, and reported there were no safety issues and recommended to continue the trial with no changes to the protocol.
    • 16 Mar 2018 Planned End Date changed from 1 Nov 2020 to 1 Apr 2021.
    • 16 Mar 2018 Planned primary completion date changed from 1 Nov 2019 to 1 Apr 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top